FDA Approves Vabrinty (leuprolide acetate) for Advanced Prostate Cancer

Photo by ika ika / Unsplash

FDA Published May 12, 2026 Medically reviewed May 12, 2026 DOI ↗ By Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development

Key Takeaway

Consider Vabrinty as a GnRH agonist option for advanced prostate cancer with flexible subcutaneous dosing intervals.

The FDA has approved Vabrinty (leuprolide acetate) for the treatment of advanced prostate cancer. Vabrinty is a gonadotropin-releasing hormone (GnRH) agonist that provides continuous release of leuprolide acetate over one, three, four, or six months. The approval offers clinicians flexible dosing options for patients with advanced prostate cancer. Vabrinty is administered subcutaneously by a healthcare provider and must be prepared and injected according to specific instructions. The label does not include clinical trial data, so the efficacy and safety profile should be considered based on the known class effects of GnRH agonists. This approval adds to the available treatment options for advanced prostate cancer.

＋ Clinical Details (Mechanism · Dosing · Trial Data · Warnings)

Mechanism of Action

Vabrinty is a gonadotropin-releasing hormone (GnRH) agonist. Continuous administration results in suppression of pituitary gonadotropin secretion, leading to reduced testosterone levels.

Indication & Patient Population

Vabrinty is indicated for the treatment of advanced prostate cancer.

Dosing & Administration

Vabrinty is administered subcutaneously by a healthcare provider. Recommended doses: 7.5 mg every month, 22.5 mg every 3 months, 30 mg every 4 months, or 45 mg every 6 months. The injection site should vary and be in an area with sufficient soft or loose subcutaneous tissue, such as the upper or mid-abdominal area. Preparation requires mixing the product within 30 minutes of administration and using the co-packaged safety needle.

Key Clinical Trial Data

Not reported in label.

Warnings & Contraindications

Not reported in label.

Place in Therapy

Vabrinty is a GnRH agonist for advanced prostate cancer, offering flexible dosing schedules. In patients treated with GnRH analogues for prostate cancer, treatment is usually continued upon development of metastatic castration-resistant prostate cancer.

Study Details

Study typeFda approval

PublishedFeb 2003

View Original Abstract ↓

1 INDICATIONS AND USAGE VABRINTY is indicated for the treatment of advanced prostate cancer. VABRINTY is a gonadotropin releasing hormone (GnRH) agonist indicated for the treatment of advanced prostate cancer. ( 1 )